Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,341.49 78.93 0.49%
S&P 500 1,849.05 6.07 0.33%
NASDAQ 4,047.77 13.61 0.34%
Ticker Volume Price Price Delta
STOXX 50 3,124.58 33.06 1.07%
FTSE 100 6,572.99 31.38 0.48%
DAX 9,270.18 96.47 1.05%
Ticker Volume Price Price Delta
NIKKEI 14,417.68 420.87 3.01%
TOPIX 1,166.55 30.46 2.68%
HANG SENG 22,696.01 24.75 0.11%

Mylan Launches Generic Version of Atacand HCT®



                Mylan Launches Generic Version of Atacand HCT®

-Company awarded 180 days marketing exclusivity on 32/25 mg strength-

PR Newswire

PITTSBURGH, Dec. 5, 2012

PITTSBURGH, Dec. 5, 2012 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today
announced that its subsidiary Mylan Pharmaceuticals Inc. has received final
approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated
New Drug Application (ANDA) for Candesartan Cilexetil and Hydrochlorothiazide
Tablets, 16/12.5 mg, 32/12.5 mg and 32/25 mg. This product is the generic
version of AstraZeneca's Atacand HCT^®, and is indicated for the treatment of
hypertension. This fixed dose combination is not indicated for initial
therapy.(1)  

Mylan was the first company to have submitted a substantially complete ANDA to
the FDA containing a Paragraph IV certification for Candesartan Cilexetil and
Hydrochlorothiazide Tablets, 32/25 mg, and was awarded 180 days of generic
drug marketing exclusivity for this product strength. Mylan is shipping all
approved strengths of this product immediately.

Atacand HCT had U.S. sales of $56.3 million for the 12 months ending Sept. 30,
2012, according to IMS Health.

Currently, Mylan has 178 ANDAs pending FDA approval representing $80.1 billion
in annual sales, according to IMS Health. Thirty-five of these pending ANDAs
are potential first-to-file opportunities, representing $21.2 billion in
annual brand sales, for the 12 months ending June 30, 2012, according to IMS
Health.

Mylan is a global pharmaceutical company committed to setting new standards in
health care. Working together around the world to provide 7 billion people
access to high quality medicine, we innovate to satisfy unmet needs; make
reliability and service a habit, do what's right, not what's easy and impact
the future through passionate global leadership. We offer a growing portfolio
of more than 1,100 generic pharmaceuticals and several brand medications. In
addition, we offer a wide range of antiretroviral therapies, upon which
approximately one-third of HIV/AIDS patients in developing countries depend.
We also operate one of the largest active pharmaceutical ingredient
manufacturers and currently market products in approximately 150 countries and
territories. Our workforce of more than 18,000 people is dedicated to
improving the customer experience and increasing pharmaceutical access to
consumers around the world. But don't take our word for it. See for yourself.
See inside. mylan.com 

(1) Candesartan Cilexetil and Hydrochlorothiazide Tablets can cause injury and
death to the developing fetus and therefore should be discontinued if
pregnancy occurs. This product is contraindicated in patients who are
hypersensitive to any component of this product or to other
sulfonamide-derived drugs and in patients with anuria. Other precautions
include: excessive reductions in blood pressure, decreased renal function,
allergic reactions, exacerbation or activation of systemic lupus erthematosus,
drug interactions with lithium, potassium and electrolyte abnormalities,
visual changes and metabolic disturbances.  If any of these conditions occur
or are suspected, medical attention should be sought.

SOURCE Mylan Inc.

Website: http://mylan.com
Contact: Nina Devlin (Media), +1-724.514.1968, or Kris King (Investors),
+1-724.514.1813
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement